World-First Registry Sheds Light on Rare Eye Cancer Affecting Both Eyes in Majority of Patients

Australian researchers have published landmark findings from the world's largest global registry dedicated to vitreoretinal lymphoma, offering eyecare clinicians new tools to identify this aggressive and frequently misdiagnosed cancer earlier.

A study led by Flinders University ophthalmologist Professor Justine Smith has delivered the most comprehensive picture yet of how vitreoretinal lymphoma (VRL) presents at diagnosis, data that could directly change how clinicians in Australia and abroad approach unexplained ocular inflammation.

The findings, published in Clinical & Experimental Ophthalmology, draw on the International Vitreoretinal B-Cell Lymphoma Registry and include data from 138 newly diagnosed patients across Europe, the Americas, the Western Pacific and South-East Asia.

Vitreoretinal lymphoma is a rare cancer that begins inside the eye but often mimics simple eye inflammation, meaning many patients are treated for the wrong condition before the cancer is recognised. For eyecare professionals, this diagnostic ambiguity is a familiar clinical challenge and one with potentially serious consequences.

The cancer can cause permanent vision loss and, in many cases, is linked with lymphoma in the brain. Earlier diagnosis helps protect sight, reduces patient distress, and ensures urgent medical checks for possible brain involvement.

The registry cohort offers several clinically significant findings that practitioners should be aware of:

Most patients are in their sixties, although men often develop symptoms at a younger age than women. Close to two-thirds of patients have the cancer in both eyes at the time of diagnosis.

Critically, for about one in four patients, the cancer is already present in the brain or elsewhere in the body when the eye disease is first identified underscoring the importance of systemic workup when VRL is suspected.

On the diagnostic front, doctors typically identify early signs of the cancer through standard eye exams and imaging commonly used in everyday practice, with these tests revealing subtle changes that prompt specialists to investigate further.

The study also delivered a finding that has long eluded researchers: the vast majority of patients have the same type of lymphoma — a finding that has been difficult to establish until now, and one that global data collection has finally made possible.

Vision loss varies widely among patients. While many still have useful vision when the cancer is found, others are already experiencing serious sight impairment, a pattern that can inform both clinical conversations and treatment planning.

Professor Smith, from FHMRI Eye & Vision at Flinders University, says the registry is filling a knowledge gap that has long hampered care for this patient group.

"Delayed diagnosis of this eye cancer can carry serious consequences, but our findings offer practical information that will help clinicians consider the disease earlier, which can protect vision and reveal cases linked to brain lymphoma," she said.

She noted that the registry's strength lies in its collaborative, multi-centre design: "It collects real‑world clinical information from multiple countries using a shared protocol, enabling researchers to detect trends that would otherwise go unnoticed. In this way, patient experiences contribute to discoveries that can improve diagnosis and care."

As more centres join the registry, researchers will be able to track how patients' vision changes over time and evaluate which treatments work best for long-term survival. The next stages of research will focus on improving outcomes and supporting people living with this challenging cancer.